Search results for #TheBiocenturyShow
Expect pharmas to start embracing more upstream risk, says Gil Bar-Nahum from @Jefferies in conversation with @FishburnSimone. M&A in the face of the upcoming patent cliff; the state of the markets; and the U.K. biotech sector - on #TheBioCenturyShow buff.ly/47d5Hk8
Aspiring biotech hubs often wonder what they need beyond good science, capital and people. @SteveBatesUK talked to me about some of the behind the scenes work of @BIA_UK in helping UK become a major center for biotech growth. On #TheBioCenturyShow. biocentury.com/article/649292…
Very much enjoyed talking with @GileadSciences CMO Merdad Parsey about $GILD pipeline, how it's building oncology, and his broad thoughts on how the bar is rising on innovation, and why that's a good thing. @BioCentury #TheBioCenturyShow biocentury.com/article/647334…
One of my top interviews for #TheBioCenturyShow was with @Amgen head of R&D David Reese, covering the promise and challenges of omics; lessons and misses 10 yrs after the DeCode aqn, and more. Interesting and insightful as ever! @BioCentury. youtu.be/r1_Cd0XWqjY via @YouTube
On #TheBioCenturyShow, @GSK’s Tony Wood talks with @FishburnSimone about the use of oligonucleotides and other modalities, coupled with genomics, as opening “a whole new arena” for the company. View full story, free with Reg: bit.ly/3HTtQ5Z #oncology #biotech #pharma
Our CSO, Tony Wood, joined @BioCentury Editor in Chief @FishburnSimone for a discussion on our approach to R&D, including our focus on areas like #infectiousddiseases. Register for free access: gsk.to/3FVGlg0 #pharma #oncology #researchanddevelopment #thebiocenturyshow
#TheBioCenturyShow is the only place where BioCentury’s experts join top #innovators and global influencers to show how science is being turned into #medicine. Join us every two weeks, available by video or audio. Register for open access > ow.ly/HJzE50Lwvxa
The one where I tell Andy "gender diversity" usually means men are normal but women "diverse," plus: we chat about big issues, eg pharmas continuing pandemic collaboration to solve structural problems @TakedaPharma @BioCentury #TheBioCenturyShow. biocentury.com/article/645713…
.@TakedaPharma's Andy Plump joins @BioCentury Editor in Chief @FishburnSimone on the latest episode of #TheBioCenturyShow & discusses how & why collaboration among pharmas that began in the pandemic can and must continue. Tune in: biocentury.com/article/645713
Turning Science into Medicine. Tune in to #BioCentury’s in-depth conversations with global #biotech and #publichealth leaders who are determining the future of #lifesciences and #medicine. Register for open access > ow.ly/3s8f50LkGhh #TheBiocenturyShow
The latest on #TheBiocenturyShow - Nora Volkow, director of @NIH (@NIDAnews) sees potential for progress on addiction disorders and discusses the importance of #innovation in the biology of substance abuse disorders. Tune in now (free with registration) ow.ly/CcrQ50LkBlf
Optimism vs obstacles: @NIH's NIDA Director Nora Volkow sees potential for progress on addiction disorders. In conversation with @BioCentury's @FishburnSimone on #TheBioCenturyShow biocentury.com/article/645565 @NIDAnews
Addiction research is seeing progress, but reimbursement and policy hurdles are obstacles to companies getting involved, says Nora Volkow, director of @NIH's @NIDAnews, on #TheBioCenturyShow. buff.ly/3sdxKxi
New on #TheBioCenturyShow - @kiranshaw shares how she built @Bioconlimited into one of the largest #biosimilars players in the US & Europe. ow.ly/SRX150Lcsb3
The latest edition of #TheBioCenturyShow features pioneering Indian entrepreneur @kiranshaw of @Bioconlimited in conversation with @BioCentury's @steveusdin1. Tune in to hear about Biocon's path to affordable innovation (free w/registration): biocentury.com/article/645408
Biocon’s path to affordable innovation: A conversation with Kiran Mazumdar Shaw on #TheBioCenturyShow. @kiranshaw @BioconBiologics buff.ly/3ylUZJa
How the Inflation Reduction Act is forcing @Novartis to rethink its pipeline. CEO @VasNarasimhan explains to @BioCentury Washington Editor @steveusdin1 how the IRA has distorted the U.S. drug market on the latest #TheBioCenturyShow (free with registration) biocentury.com/article/645066
From Morgan Stanley to Juno to Sana: Steve Harr joins #TheBioCenturyShow to discuss gene & cell therapies -- from tech to talent - with @BioCentury's @FishburnSimone. Tune In: biocentury.com/article/644764
Complexity is the attraction: Sana CEO Steve Harr speaks with #TheBioCenturyShow's @FishburnSimone on the pull of cell and gene therapy buff.ly/3zGHELm
Our Founder, Chair and CEO Samantha Du recently sat down with @BioCentury and provided her thoughts on how a diverse culture fuels innovation and creativity in today's biopharma industry. Watch the full interview here: bit.ly/3tAS7FS. #TheBioCenturyShow
Our Founder, Chair and CEO Samantha Du recently sat down with @BioCentury and provided her thoughts on how a diverse culture fuels innovation and creativity in today's biopharma industry. Watch the full interview here: bit.ly/3tAS7FS. #TheBioCenturyShow